Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease
- PMID: 20582568
- DOI: 10.1007/s11064-010-0222-3
Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease
Abstract
The current investigation compared intranigral lipopolysaccharide (LPS), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) administrations, in the light of neurochemical, behavioral and endogenous antioxidant glutathione alterations. All the results were collected 1, 3 and 7 days after the lesions. LPS produced a delayed reduction of striatal dopamine, whereas homovanillic acid was drastically increased at the first time-point. Comparatively, MPTP promoted dopamine reduction 3 and 7 days with increase of homovanillic acid. Whilst, 6-OHDA generated initial increase of dopamine and homovanillic acid followed by subsequent decrease of this neurotransmitter accompanied by reductions of dopamine metabolites at the same periods. Furthermore, nigral glutathione demonstrated to be a far more sensitive target for LPS than for MPTP or 6-OHDA. Behavioral data indicated impairments induced by MPTP, 6-OHDA but not LPS. In conclusion, it is suggested that intranigral LPS can provide new insights about neuroinflammation, simulating features of the pre-motor phase of Parkinson's disease.
Similar articles
-
Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1104-14. doi: 10.1016/j.pnpbp.2010.06.004. Epub 2010 Jun 12. Prog Neuropsychopharmacol Biol Psychiatry. 2010. PMID: 20547199
-
Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin.Behav Brain Res. 2014 Feb 1;259:70-7. doi: 10.1016/j.bbr.2013.10.035. Epub 2013 Oct 30. Behav Brain Res. 2014. PMID: 24183944
-
Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.J Neurosci Methods. 2005 Oct 15;148(1):78-87. doi: 10.1016/j.jneumeth.2005.04.005. Epub 2005 Jun 6. J Neurosci Methods. 2005. PMID: 15939479
-
[Experimental models, of Parkinson disease].Rev Neurol. 2000 Jul 1-15;31(1):60-6. Rev Neurol. 2000. PMID: 10948587 Review. Spanish.
-
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.J Neural Transm Suppl. 1986;20:11-39. J Neural Transm Suppl. 1986. PMID: 3091760 Review.
Cited by
-
The endotoxin-induced neuroinflammation model of Parkinson's disease.Parkinsons Dis. 2011 Jan 18;2011:487450. doi: 10.4061/2011/487450. Parkinsons Dis. 2011. PMID: 21331154 Free PMC article.
-
Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy.Cell Mol Neurobiol. 2022 Jul;42(5):1283-1300. doi: 10.1007/s10571-020-01027-6. Epub 2021 Jan 2. Cell Mol Neurobiol. 2022. PMID: 33387119 Free PMC article. Review.
-
Aspirin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity in primary midbrain cultures.J Mol Neurosci. 2012 Jan;46(1):153-61. doi: 10.1007/s12031-011-9541-3. Epub 2011 May 17. J Mol Neurosci. 2012. PMID: 21584653
-
Crosstalk between neuroinflammation and oxidative stress in epilepsy.Front Cell Dev Biol. 2022 Aug 10;10:976953. doi: 10.3389/fcell.2022.976953. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36035987 Free PMC article. Review.
-
Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.Neurotox Res. 2012 Apr;21(3):291-301. doi: 10.1007/s12640-011-9278-3. Epub 2011 Sep 28. Neurotox Res. 2012. PMID: 21953489
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical